CA2310926C - A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease - Google Patents

A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease Download PDF

Info

Publication number: CA2310926C
Authority: CA; Canada
Prior art keywords: day; galantamine; treatment; weeks; dosage
Prior art date: 2000-04-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002310926A

Other languages

English (en)

French (fr)

Other versions

CA2310926A1 (en

Inventor

Wim Louis Julien Parys

Michael Pontecorvo

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Janssen Pharmaceutica NV

Original Assignee

Janssen Pharmaceutica NV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-03

Filing date

2000-06-27

Publication date

2002-10-15

2000-06-27 Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV

2000-10-04 Publication of CA2310926A1 publication Critical patent/CA2310926A1/en

2002-10-15 Application granted granted Critical

2002-10-15 Publication of CA2310926C publication Critical patent/CA2310926C/en

2020-06-27 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title claims abstract description 127
229960003980 galantamine Drugs 0.000 title claims abstract description 64
ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 title claims abstract description 61
208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 23
239000003814 drug Substances 0.000 claims description 13
150000003839 salts Chemical class 0.000 claims description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
208000017667 Chronic Disease Diseases 0.000 abstract description 3
230000000087 stabilizing effect Effects 0.000 abstract 1
239000000902 placebo Substances 0.000 description 28
229940068196 placebo Drugs 0.000 description 28
230000008859 change Effects 0.000 description 19
238000012360 testing method Methods 0.000 description 16
230000006399 behavior Effects 0.000 description 15
229940079593 drug Drugs 0.000 description 12
230000002411 adverse Effects 0.000 description 11
102100039554 Galectin-8 Human genes 0.000 description 10
101001011019 Gallus gallus Gallinacin-10 Proteins 0.000 description 10
101000887168 Gallus gallus Gallinacin-8 Proteins 0.000 description 10
BLGKYYVFGMKTEZ-QVCIKPHISA-N D-galactosyl-N-hexadecanoylsphinganine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)CCCCCCCCCCCCCCC)COC1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BLGKYYVFGMKTEZ-QVCIKPHISA-N 0.000 description 9
SNPQGCDJHZAVOB-LUUMFRNDSA-N D-galactosyl-N-tetracosanoylsphinganine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)CCCCCCCCCCCCCCC)COC1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O SNPQGCDJHZAVOB-LUUMFRNDSA-N 0.000 description 9
230000000694 effects Effects 0.000 description 9
206010042772 syncope Diseases 0.000 description 9
102100034112 Alkyldihydroxyacetonephosphate synthase, peroxisomal Human genes 0.000 description 8
101000799143 Homo sapiens Alkyldihydroxyacetonephosphate synthase, peroxisomal Proteins 0.000 description 8
238000000848 angular dependent Auger electron spectroscopy Methods 0.000 description 8
230000001149 cognitive effect Effects 0.000 description 8
238000012423 maintenance Methods 0.000 description 7
238000004458 analytical method Methods 0.000 description 6
238000000034 method Methods 0.000 description 6
208000035475 disorder Diseases 0.000 description 5
238000004448 titration Methods 0.000 description 5
238000007492 two-way ANOVA Methods 0.000 description 5
238000013019 agitation Methods 0.000 description 4
230000006872 improvement Effects 0.000 description 4
206010028813 Nausea Diseases 0.000 description 3
206010047700 Vomiting Diseases 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
229930013930 alkaloid Natural products 0.000 description 3
230000003542 behavioural effect Effects 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000034994 death Effects 0.000 description 3
231100000517 death Toxicity 0.000 description 3
230000006866 deterioration Effects 0.000 description 3
230000002526 effect on cardiovascular system Effects 0.000 description 3
208000014674 injury Diseases 0.000 description 3
230000008693 nausea Effects 0.000 description 3
238000012216 screening Methods 0.000 description 3
230000008673 vomiting Effects 0.000 description 3
206010001497 Agitation Diseases 0.000 description 2
208000007848 Alcoholism Diseases 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
206010002942 Apathy Diseases 0.000 description 2
208000019888 Circadian rhythm sleep disease Diseases 0.000 description 2
206010012239 Delusion Diseases 0.000 description 2
206010012735 Diarrhoea Diseases 0.000 description 2
206010013142 Disinhibition Diseases 0.000 description 2
206010013954 Dysphoria Diseases 0.000 description 2
241001539473 Euphoria Species 0.000 description 2
206010015535 Euphoric mood Diseases 0.000 description 2
208000004547 Hallucinations Diseases 0.000 description 2
206010022998 Irritability Diseases 0.000 description 2
208000001456 Jet Lag Syndrome Diseases 0.000 description 2
206010026749 Mania Diseases 0.000 description 2
206010057852 Nicotine dependence Diseases 0.000 description 2
208000025569 Tobacco Use disease Diseases 0.000 description 2
230000001594 aberrant effect Effects 0.000 description 2
230000016571 aggressive behavior Effects 0.000 description 2
201000007930 alcohol dependence Diseases 0.000 description 2
150000003797 alkaloid derivatives Chemical group 0.000 description 2
208000022531 anorexia Diseases 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
230000002917 arthritic effect Effects 0.000 description 2
230000036471 bradycardia Effects 0.000 description 2
208000006218 bradycardia Diseases 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000000544 cholinesterase inhibitor Substances 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
206010061428 decreased appetite Diseases 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
231100000868 delusion Toxicity 0.000 description 2
238000009472 formulation Methods 0.000 description 2
229940006388 galantamine 8 mg Drugs 0.000 description 2
QORVDGQLPPAFRS-XPSHAMGMSA-N galantamine hydrobromide Chemical compound Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 description 2
230000003993 interaction Effects 0.000 description 2
208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 2
230000007074 memory dysfunction Effects 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
210000001635 urinary tract Anatomy 0.000 description 2
GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 1
HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
206010000117 Abnormal behaviour Diseases 0.000 description 1
102100033639 Acetylcholinesterase Human genes 0.000 description 1
108010022752 Acetylcholinesterase Proteins 0.000 description 1
229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
241001535291 Analges Species 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 description 1
229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
102000003914 Cholinesterases Human genes 0.000 description 1
108090000322 Cholinesterases Proteins 0.000 description 1
241001111317 Chondrodendron tomentosum Species 0.000 description 1
238000000959 Cochran–Mantel–Haenszel (CMH) test Methods 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
239000008709 Curare Substances 0.000 description 1
206010013486 Distractibility Diseases 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000001375 Facial Neuralgia Diseases 0.000 description 1
241000234271 Galanthus Species 0.000 description 1
241001502107 Galanthus alpinus Species 0.000 description 1
241000234283 Galanthus nivalis Species 0.000 description 1
208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
101001005711 Homo sapiens MARVEL domain-containing protein 2 Proteins 0.000 description 1
102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
208000010428 Muscle Weakness Diseases 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
241000234479 Narcissus Species 0.000 description 1
102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
DITOENWBJBNZSL-UHFFFAOYSA-N O-methyl-hippeastrine Natural products C1=C2C3C4N(C)CCC4=CC(OC)C3OC(=O)C2=CC2=C1OCO2 DITOENWBJBNZSL-UHFFFAOYSA-N 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
101100532451 Rattus norvegicus Slc22a17 gene Proteins 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
229940022698 acetylcholinesterase Drugs 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
201000007201 aphasia Diseases 0.000 description 1
206010003549 asthenia Diseases 0.000 description 1
229940054371 atropine / neostigmine Drugs 0.000 description 1
210000000270 basal cell Anatomy 0.000 description 1
238000003287 bathing Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229940048961 cholinesterase Drugs 0.000 description 1
230000000718 cholinopositive effect Effects 0.000 description 1
230000002060 circadian Effects 0.000 description 1
230000006999 cognitive decline Effects 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
230000003931 cognitive performance Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
208000012790 cranial neuralgia Diseases 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
229960002024 galantamine hydrobromide Drugs 0.000 description 1
BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 description 1
230000003370 grooming effect Effects 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000015654 memory Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
-1 pessaries Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
239000012313 reversal agent Substances 0.000 description 1
238000012552 review Methods 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
230000006403 short-term memory Effects 0.000 description 1
235000011888 snacks Nutrition 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
201000005060 thrombophlebitis Diseases 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000002562 urinalysis Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines Containing Plant Substances (AREA)

CA002310926A 2000-04-03 2000-06-27 A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease Expired - Lifetime CA2310926C (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US19425900P	2000-04-03	2000-04-03
US60/194,259		2000-04-03

Publications (2)

Publication Number	Publication Date
CA2310926A1 CA2310926A1 (en)	2000-10-04
CA2310926C true CA2310926C (en)	2002-10-15

Family

ID=22716898

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002310926A Expired - Lifetime CA2310926C (en)	2000-04-03	2000-06-27	A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease

Country Status (20)

Country	Link
EP (1)	EP1272192A2 (de)
JP (1)	JP2003528913A (de)
KR (1)	KR20020086911A (de)
CN (1)	CN1430514A (de)
AU (2)	AU2001265844B2 (de)
BG (1)	BG107093A (de)
BR (1)	BR0109770A (de)
CA (1)	CA2310926C (de)
CZ (1)	CZ20023543A3 (de)
EE (1)	EE200200554A (de)
HR (1)	HRP20020778A2 (de)
HU (1)	HUP0300566A3 (de)
IL (1)	IL152061A0 (de)
MX (1)	MXPA02009777A (de)
NO (1)	NO20024746L (de)
PL (1)	PL361272A1 (de)
RU (1)	RU2002129298A (de)
SK (1)	SK15422002A3 (de)
WO (1)	WO2001074339A2 (de)
ZA (1)	ZA200207935B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6617361B2 (en) *	1999-11-05	2003-09-09	Be Able, Llc	Behavior chemotherapy
ES2293287T3 (es)	2003-07-25	2008-03-16	F. Hoffmann-La Roche Ag	Combinacion de antagonista de mglur2 y de inhibidor de ache para el tratamiento de trastornos neurologicos agudos y/o cronicos.
DE10338544B4 (de) *	2003-08-19	2017-08-31	Janssen Pharmaceutica N.V.	Buccale Formulierungen des Galanthamins und deren Anwendungen
AU2009229372C1 (en)	2008-03-27	2017-02-02	Chase Pharmaceuticals Corporation	Use and composition for treating dementia
WO2013160728A1 (en)	2012-04-26	2013-10-31	Alma Mater Studiorum - Universita' Di Bologna	Dual targeting compounds for the treatment of alzheimer's disease
BG66818B1 (bg) *	2013-03-07	2019-01-31	Berbee Beheer B. V.	Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки
AU2016264228B2 (en) *	2015-05-18	2019-06-13	Synaptec Development Llc	Galantamine clearance of amyloidß
WO2023036105A1 (zh) *	2021-09-09	2023-03-16	上海日馨医药科技股份有限公司	治疗神经退行性疾病的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4663318A (en) *	1986-01-15	1987-05-05	Bonnie Davis	Method of treating Alzheimer's disease
DE19509663A1 (de) *	1995-03-17	1996-09-19	Lohmann Therapie Syst Lts	Verfahren zur Isolierung von Galanthamin
GB9600080D0 (en) *	1996-01-04	1996-03-06	Chiroscience Ltd	Resolution process
AU1738800A (en)	1998-11-23	2000-06-13	Bonnie Davis	Dosage formulations for acetylcholinesterase inhibitors
AU775914B2 (en) *	1998-12-24	2004-08-19	Janssen Pharmaceutica N.V.	Controlled release galantamine composition
CA2310950C (en) *	2000-04-03	2005-11-08	Janssen Pharmaceutica N.V.	An efficacious dosage regiment of galantamine that reduces side effects
CA2310990A1 (en) *	2000-04-03	2000-10-09	Michael Pontecorvo	A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease

2000
- 2000-06-27 CA CA002310926A patent/CA2310926C/en not_active Expired - Lifetime
2001
- 2001-03-28 EP EP01943200A patent/EP1272192A2/de not_active Withdrawn
- 2001-03-28 RU RU2002129298/14A patent/RU2002129298A/ru not_active Application Discontinuation
- 2001-03-28 PL PL36127201A patent/PL361272A1/xx not_active Application Discontinuation
- 2001-03-28 KR KR1020027011063A patent/KR20020086911A/ko not_active Ceased
- 2001-03-28 SK SK1542-2002A patent/SK15422002A3/sk unknown
- 2001-03-28 AU AU2001265844A patent/AU2001265844B2/en not_active Ceased
- 2001-03-28 BR BR0109770-9A patent/BR0109770A/pt not_active IP Right Cessation
- 2001-03-28 HR HR20020778A patent/HRP20020778A2/xx not_active Application Discontinuation
- 2001-03-28 HU HU0300566A patent/HUP0300566A3/hu unknown
- 2001-03-28 CN CN01807334A patent/CN1430514A/zh active Pending
- 2001-03-28 WO PCT/EP2001/003553 patent/WO2001074339A2/en not_active Ceased
- 2001-03-28 CZ CZ20023543A patent/CZ20023543A3/cs unknown
- 2001-03-28 EE EEP200200554A patent/EE200200554A/xx unknown
- 2001-03-28 IL IL15206101A patent/IL152061A0/xx unknown
- 2001-03-28 MX MXPA02009777A patent/MXPA02009777A/es unknown
- 2001-03-28 AU AU6584401A patent/AU6584401A/xx active Pending
- 2001-03-28 JP JP2001572084A patent/JP2003528913A/ja not_active Withdrawn
2002
- 2002-09-12 BG BG107093A patent/BG107093A/bg unknown
- 2002-10-02 NO NO20024746A patent/NO20024746L/no not_active Application Discontinuation
- 2002-10-02 ZA ZA200207935A patent/ZA200207935B/en unknown

Also Published As

Publication number	Publication date
RU2002129298A (ru)	2004-03-27
KR20020086911A (ko)	2002-11-20
HUP0300566A2 (hu)	2003-06-28
BG107093A (bg)	2003-06-30
PL361272A1 (en)	2004-10-04
AU6584401A (en)	2001-10-15
WO2001074339A3 (en)	2002-09-12
HUP0300566A3 (en)	2004-10-28
WO2001074339A2 (en)	2001-10-11
NO20024746D0 (no)	2002-10-02
NO20024746L (no)	2002-11-28
CA2310926A1 (en)	2000-10-04
AU2001265844B2 (en)	2005-04-14
SK15422002A3 (sk)	2003-04-01
CZ20023543A3 (cs)	2003-03-12
BR0109770A (pt)	2003-02-04
ZA200207935B (en)	2004-01-30
EE200200554A (et)	2004-04-15
MXPA02009777A (es)	2003-03-27
HRP20020778A2 (en)	2004-04-30
EP1272192A2 (de)	2003-01-08
IL152061A0 (en)	2003-05-29
CN1430514A (zh)	2003-07-16
JP2003528913A (ja)	2003-09-30

Legal Events

Date	Code	Title	Description
2000-06-27	EEER	Examination request
2020-08-31	MKEX	Expiry	Effective date: 20200629

Publication	Publication Date	Title
AU621035B2 (en)	1992-03-05	The administration of monoamine acridines in cholinergic neuronal deficit states
Granacher et al.	1975	Physostigmine: Its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs
JP4097285B2 (ja)	2008-06-11	種々の頑固な疾患の治療のための医薬の製造に有用な組成物
CA2310950C (en)	2005-11-08	An efficacious dosage regiment of galantamine that reduces side effects
KR20220012281A (ko)	2022-02-03	브루톤 티로신 키나제 저해제를 이용하여 만성 자발성 두드러기를 치료하는 방법
CA2310926C (en)	2002-10-15	A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
AU2001265844A1 (en)	2002-01-03	A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
Dalton et al.	1986	Cimetidine and carbamazepine: a complex drug interaction
US7943632B2 (en)	2011-05-17	High potency dopaminergic treatment of neurological impairment associated with brain injury
US20060172993A1 (en)	2006-08-03	Use of galantamine for the treatment of neuropsychiatric behaviour associated with Alzheimer's disease
Stanaland	2002	Treatment of patients with chronic idiopathic urticaria
WO2015153263A1 (en)	2015-10-08	Compositions and methods to treat addiction
US12023315B2 (en)	2024-07-02	Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
US20050203105A1 (en)	2005-09-15	Composition and method for controlling alcohol-induced facial flushing in susceptible humans
RU2847617C2 (ru)	2025-10-10	Способы лечения хронической спонтанной крапивницы с применением ингибитора тирозинкиназы брутона
Panas et al.	2018	Belladonna alkaloids and phenobarbital use in the treatment of irritable bowel syndrome: a review
Flowers et al.	1986	Antihistamines.
RU2818678C2 (ru)	2024-05-03	Способы лечения хронической спонтанной крапивницы с применением ингибитора тирозинкиназы брутона
US11752141B2 (en)	2023-09-12	Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
JP2005306882A (ja)	2005-11-04	感情的不安定の治療のための医薬の製造に有用な組成物
JP4372723B2 (ja)	2009-11-25	慢性疼痛の治療のための医薬の製造に有用な組成物
CA2310990A1 (en)	2000-10-09	A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease
Patsalos et al.	1990	The efficacy and tolerability of chewable carbamazepine compared to conventional carbamazepine in patients with epilepsy
de Haen	1971	Annual Review of New Drugs